ABSTRACT
Dopamine agonists provide an effective means of treating early, middle, and late stages
of Parkinson's disease. This article outlines the advantages and disadvantages of
dopamine agonists as compared with levodopa therapy. The features and costs of the
four Food and Drug Administration-approved agonists (bromocriptine, pergolide, pramipexole,
and ropinirole) and apomorphine, another agonist presently under investigation, are
discussed.
KEYWORD
Dopamine agonists - Parkinson's disease - Parkinson's disease treatment
